Literature DB >> 17294226

Meningococcal disease associated with an acute post-streptococcal complement deficiency.

Nikolaos Daskas1, Katie Farmer, Richard Coward, Michel Erlewyn-Lajeunesse.   

Abstract

Chronic deficiencies in the complement pathway proteins are associated with an increased risk of meningococcal disease. Such deficiencies are caused by primary congenital immunodeficiency of a complement protein, properdin or mannose binding lectin, or are secondary to consumption of complement by systemic lupus erythematosus (SLE) or membranoproliferative glomerulonephritis (MPGN). Whatever the cause, the complement deficiency is always chronic. Here we report a case of meningococcal disease (MCD) in a child with a transient complement deficiency (CD), caused by post-streptococcal glomerulonephritis (PSGN).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294226     DOI: 10.1007/s00467-006-0394-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Occurrence of subclinical post-streptococcal glomerulonephritis in family contacts.

Authors:  V Tasic; M Polenakovic
Journal:  J Paediatr Child Health       Date:  2003-04       Impact factor: 1.954

2.  Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.

Authors:  Michael Pichichero; Janet Casey; Mark Blatter; Edward Rothstein; Robert Ryall; Mike Bybel; Gregory Gilmet; Thomas Papa
Journal:  Pediatr Infect Dis J       Date:  2005-01       Impact factor: 2.129

3.  Hypocomplementaemia and septicaemia.

Authors:  Denis G Gill; Adrienne Foran
Journal:  Pediatr Nephrol       Date:  2005-05       Impact factor: 3.714

Review 4.  Complement and properidin deficiencies in meningococcal disease.

Authors:  Susan Mathew; Gary D Overturf
Journal:  Pediatr Infect Dis J       Date:  2006-03       Impact factor: 2.129

Review 5.  Complement deficiencies and meningococcal disease.

Authors:  P Densen
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

6.  Serum complement levels before and after the onset of acute post-streptococcal glomerulonephritis. A case report.

Authors:  C F Strife; T J Forristal; J Forristal
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

7.  Investigation for complement deficiency following meningococcal disease.

Authors:  S Hoare; O El-Shazali; J E Clark; A Fay; A J Cant
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

8.  Anti-streptococcal antibodies in the diagnosis of acute and post-streptococcal disease: streptokinase versus streptolysin O and deoxyribonuclease B.

Authors:  C C Blyth; P W Robertson
Journal:  Pathology       Date:  2006-04       Impact factor: 5.306

9.  Extremity pain and refusal to walk in children with invasive meningococcal disease.

Authors:  Stanley H Inkelis; Daniel O'Leary; Vincent J Wang; Richard Malley; Martha K Nicholson; Nathan Kuppermann
Journal:  Pediatrics       Date:  2002-07       Impact factor: 7.124

10.  Systemic meningococcal infections in patients with acquired complement deficiency.

Authors:  B Z Garty; M Nitzan; Y L Danon
Journal:  Pediatr Allergy Immunol       Date:  1993-02       Impact factor: 6.377

View more
  3 in total

Review 1.  Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.

Authors:  E David McIntosh; Victor Carey; Daniela Toneatto; Peter Dull; James Wassil
Journal:  Ther Adv Vaccines       Date:  2015-01

Review 2.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 3.  Meningococcal disease and the complement system.

Authors:  Lisa A Lewis; Sanjay Ram
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.